- Home
- ACRV vs NTRB Comparison
ACRV vs NTRB Comparison
Compare ACRV & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | NTRB |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 71.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | NTRB |
|---|---|---|
| Price | $2.39 | $4.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $14.67 | $13.00 |
| AVG Volume (30 Days) | ★ 1.3M | 21.7K |
| Earning Date | 11-13-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,578,059.00 |
| Revenue This Year | N/A | $560.75 |
| Revenue Next Year | $805.34 | $588.39 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.92 |
| 52 Week Low | $1.05 | $3.72 |
| 52 Week High | $8.00 | $11.78 |
Technical Indicators
Market Signals| Indicator | ACRV | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 30.74 |
| Support Level | $2.22 | $4.59 |
| Resistance Level | $2.39 | $4.99 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 86.15 | 12.52 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.